Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T22:33:15.056Z.
Calculation as of: 2026-10-06T22:33:15.056Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 680db3c2305e98602fe5277f15244516f30a0ab53cbf5830e5b41f5092839f7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
SL Science Holding Ltd
Market Cap
$852.35M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$853.13M
Operating Cash Flow Yield
9.31%
TTM Avg
10.90%
3Y Avg
9.30%
5Y Avg
6.80%
Market Cap
$857.16M
Operating Cash Flow Yield
N/A
TTM Avg
5.54%
3Y Avg
5.51%
5Y Avg
9.92%
Market Cap
$838.62M
Operating Cash Flow Yield
N/A
TTM Avg
1.45%
3Y Avg
1.45%
5Y Avg
1.45%
Market Cap
$838.16M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.03M
Operating Cash Flow Yield
0.29%
TTM Avg
0.28%
3Y Avg
0.28%
5Y Avg
0.28%
Market Cap
$870.81M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
Operating Cash Flow Yield
N/A
TTM Avg
10.89%
3Y Avg
10.89%
5Y Avg
10.89%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SL Science Holding Ltd (SLBT) | $852.35M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 9.31% | 10.90% | 9.30% | 6.80% |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | N/A | 5.54% | 5.51% | 9.92% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 1.45% | 1.45% | 1.45% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | 0.29% | 0.28% | 0.28% | 0.28% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | N/A | 10.89% | 10.89% | 10.89% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
